SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'Q9G'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1OPJ_B_STIB4_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 6 LYS A 653
ILE A 697
MET A 702
ARG A 745
 Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
None
 0.72A 1opjB-2xyuA:
32.4		 1opjB-2xyuA:
38.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_A_BAXA1723_2
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 6 ILE A 627
VAL A 635
ILE A 682
ASP A 764
 None
Q9G  A1898 ( 4.7A)
None
None
 0.66A 1uwhA-2xyuA:
29.4		 1uwhA-2xyuA:
32.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWH_B_BAXB1723_2
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 6 ILE A 627
VAL A 635
ILE A 682
ASP A 764
 None
Q9G  A1898 ( 4.7A)
None
None
 0.66A 1uwhB-2xyuA:
29.1		 1uwhB-2xyuA:
32.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_A_BAXA1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
THR A 699
LEU A 737
HIS A 744
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
None
None
 0.43A 1uwjA-2xyuA:
7.8		 1uwjA-2xyuA:
33.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_A_BAXA1723_2
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 ILE A 627
LYS A 653
ILE A 682
ASP A 764
 None
Q9G  A1898 (-4.8A)
None
None
 0.83A 1uwjA-2xyuA:
7.8		 1uwjA-2xyuA:
33.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
1UWJ_B_BAXB1723_1
(B-RAF PROTO-ONCOGENE
SERINE/THREONINE-PRO
TEIN KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ILE A 627
VAL A 635
ALA A 651
THR A 699
LEU A 737
HIS A 744
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
None
None
 0.76A 1uwjB-2xyuA:
7.9		 1uwjB-2xyuA:
33.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_A_1N1A501_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.59A 2gqgA-2xyuA:
29.3		 2gqgA-2xyuA:
38.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2GQG_B_1N1B502_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.51A 2gqgB-2xyuA:
32.7		 2gqgB-2xyuA:
38.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_C_STIC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 6 LYS A 653
MET A 674
ILE A 697
MET A 702
 Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
None
 0.50A 2hyyC-2xyuA:
32.7		 2hyyC-2xyuA:
38.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2HYY_D_STID600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.78A 2hyyD-2xyuA:
27.2		 2hyyD-2xyuA:
38.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITO_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ALA A 651
LYS A 653
MET A 674
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.72A 2itoA-2xyuA:
26.5		 2itoA-2xyuA:
36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITY_A_IREA2020_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 GLY A 628
VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.55A 2ityA-2xyuA:
28.9		 2ityA-2xyuA:
36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ITZ_A_IREA2021_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.62A 2itzA-2xyuA:
28.9		 2itzA-2xyuA:
36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2IVU_A_ZD6A3015_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET
PRECURSOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		3 / 3 ALA A 651
GLY A 705
SER A 763
 Q9G  A1898 (-3.2A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-3.2A)
 0.16A 2ivuA-2xyuA:
27.4		 2ivuA-2xyuA:
34.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.61A 2oiqA-2xyuA:
27.9		 2oiqA-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2OIQ_A_STIA1001_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 0.63A 2oiqA-2xyuA:
27.9		 2oiqA-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
LEU A 753
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 0.78A 2pl0A-2xyuA:
26.0		 2pl0A-2xyuA:
41.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2PL0_A_STIA200_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE LCK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
None
 0.49A 2pl0A-2xyuA:
26.0		 2pl0A-2xyuA:
41.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2WGJ_A_VGHA2346_1
(HEPATOCYTE GROWTH
FACTOR RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 GLY A 628
VAL A 635
ALA A 651
TYR A 701
MET A 702
GLY A 705
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
 0.64A 2wgjA-2xyuA:
28.6		 2wgjA-2xyuA:
31.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2XP2_A_VGHA9000_1
(TYROSINE-PROTEIN
KINASE RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 VAL A 635
ALA A 651
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.63A 2xp2A-2xyuA:
33.8		 2xp2A-2xyuA:
34.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2Y6O_A_1N1A1892_1
(EPHRIN TYPE-A
RECEPTOR 4)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		10 / 12 ILE A 627
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.32A 2y6oA-2xyuA:
34.3		 2y6oA-2xyuA:
100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_A_B49A1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ILE A 627
VAL A 635
ALA A 651
ILE A 683
MET A 702
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.62A 2y7jA-2xyuA:
20.3		 2y7jA-2xyuA:
22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_B_B49B1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 10 ILE A 627
VAL A 635
ALA A 651
ILE A 683
MET A 702
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.58A 2y7jB-2xyuA:
18.8		 2y7jB-2xyuA:
22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_C_B49C1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 10 ILE A 627
VAL A 635
ALA A 651
ILE A 683
MET A 702
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.61A 2y7jC-2xyuA:
20.4		 2y7jC-2xyuA:
22.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2Y7J_D_B49D1294_1
(PHOSPHORYLASE B
KINASE GAMMA
CATALYTIC CHAIN,
TESTIS/LIVER ISOFORM)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 10 ILE A 627
VAL A 635
ALA A 651
ILE A 683
MET A 702
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.53A 2y7jD-2xyuA:
9.8		 2y7jD-2xyuA:
22.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2ZVA_A_1N1A513_1
(TYROSINE-PROTEIN
KINASE LYN)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.68A 2zvaA-2xyuA:
27.2		 2zvaA-2xyuA:
41.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3BBT_B_FMMB91_1
(RECEPTOR
TYROSINE-PROTEIN
KINASE ERBB-4)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
LEU A 685
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.58A 3bbtB-2xyuA:
19.2		 3bbtB-2xyuA:
34.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 10 VAL A 635
LYS A 653
ILE A 697
VAL A 762
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
None
 0.75A 3cs9A-2xyuA:
27.5		 3cs9A-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_A_NILA600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
MET A 674
THR A 699
GLY A 705
HIS A 744
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
None
 0.45A 3cs9A-2xyuA:
27.5		 3cs9A-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
MET A 674
THR A 699
GLY A 705
HIS A 744
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
None
 0.48A 3cs9B-2xyuA:
28.5		 3cs9B-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
MET A 674
THR A 699
HIS A 744
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
None
None
 0.74A 3cs9B-2xyuA:
28.5		 3cs9B-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_B_NILB600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 VAL A 635
LYS A 653
ILE A 697
LEU A 753
VAL A 762
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-4.3A)
None
 0.55A 3cs9B-2xyuA:
28.5		 3cs9B-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3CS9_C_NILC600_2
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 VAL A 635
LYS A 653
ILE A 697
MET A 702
VAL A 762
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
None
 0.47A 3cs9C-2xyuA:
32.3		 3cs9C-2xyuA:
38.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G0F_B_B49B9001_1
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 10 VAL A 635
ALA A 651
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.75A 3g0fB-2xyuA:
31.6		 3g0fB-2xyuA:
31.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_A_1N1A1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.59A 3g5dA-2xyuA:
28.1		 3g5dA-2xyuA:
42.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3G5D_B_1N1B1_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.63A 3g5dB-2xyuA:
28.1		 3g5dB-2xyuA:
42.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3GP0_A_NILA1_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 11)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
ILE A 683
THR A 699
HIS A 744
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
None
None
 0.81A 3gp0A-2xyuA:
22.1		 3gp0A-2xyuA:
25.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3GVU_A_STIA1001_2
(TYROSINE-PROTEIN
KINASE ABL2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 5 LYS A 653
ILE A 697
TYR A 701
MET A 702
 Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-4.8A)
None
 0.44A 3gvuA-2xyuA:
28.0		 3gvuA-2xyuA:
36.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K54_A_1N1A1_1
(TYROSINE-PROTEIN
KINASE BTK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
SER A 763
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.68A 3k54A-2xyuA:
33.3		 3k54A-2xyuA:
37.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3K54_A_1N1A1_1
(TYROSINE-PROTEIN
KINASE BTK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
SER A 763
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.54A 3k54A-2xyuA:
33.3		 3k54A-2xyuA:
37.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MIY_A_B49A1_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 11 ILE A 627
ALA A 651
MET A 702
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.33A 3miyA-2xyuA:
31.1		 3miyA-2xyuA:
39.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MIY_B_B49B2_1
(TYROSINE-PROTEIN
KINASE ITK/TSK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 ILE A 627
ALA A 651
MET A 702
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.30A 3miyB-2xyuA:
34.2		 3miyB-2xyuA:
39.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_B_STIB1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 LYS A 653
ILE A 697
MET A 702
ARG A 745
 Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
None
 0.84A 3mssB-2xyuA:
27.5		 3mssB-2xyuA:
38.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MSS_D_STID1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 6 VAL A 635
LYS A 653
ILE A 697
MET A 702
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
 0.50A 3mssD-2xyuA:
27.5		 3mssD-2xyuA:
38.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OCT_A_1N1A663_1
(TYROSINE-PROTEIN
KINASE BTK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.75A 3octA-2xyuA:
14.0		 3octA-2xyuA:
39.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
MET A 674
THR A 699
TYR A 701
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
None
 0.49A 3oezA-2xyuA:
28.1		 3oezA-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_A_STIA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.52A 3oezA-2xyuA:
28.1		 3oezA-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OEZ_B_STIB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 0.88A 3oezB-2xyuA:
28.0		 3oezB-2xyuA:
43.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_A_1N1A1000_1
(P38A)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 GLY A 628
VAL A 635
ALA A 651
LYS A 653
ILE A 683
THR A 699
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
 0.91A 3ohtA-2xyuA:
6.1		 3ohtA-2xyuA:
23.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_B_1N1B1000_1
(P38A)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 GLY A 628
VAL A 635
ALA A 651
LYS A 653
ILE A 683
THR A 699
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
 0.92A 3ohtB-2xyuA:
6.0		 3ohtB-2xyuA:
23.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3OHT_B_1N1B1000_1
(P38A)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 GLY A 628
VAL A 635
ALA A 651
LYS A 653
THR A 699
GLY A 705
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
 0.79A 3ohtB-2xyuA:
6.0		 3ohtB-2xyuA:
23.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ALA A 651
MET A 674
THR A 699
GLY A 705
HIS A 744
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
None
None
 0.81A 3oxzA-2xyuA:
27.1		 3oxzA-2xyuA:
38.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 ILE A 697
MET A 702
ARG A 745
LEU A 753
VAL A 762
 Q9G  A1898 ( 4.6A)
None
None
Q9G  A1898 (-4.3A)
None
 0.76A 3oxzA-2xyuA:
27.1		 3oxzA-2xyuA:
38.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3OXZ_A_0LIA1_2
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 LYS A 653
ILE A 697
MET A 702
LEU A 753
VAL A 762
 Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
Q9G  A1898 (-4.3A)
None
 0.39A 3oxzA-2xyuA:
27.1		 3oxzA-2xyuA:
38.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3PYY_B_STIB4_1
(V-ABL ABELSON MURINE
LEUKEMIA VIRAL
ONCOGENE HOMOLOG 1
ISOFORM B VARIANT)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
MET A 674
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.77A 3pyyB-2xyuA:
27.5		 3pyyB-2xyuA:
38.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3QLG_A_1N1A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.62A 3qlgA-2xyuA:
28.1		 3qlgA-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.53A 3sxrA-2xyuA:
32.1		 3sxrA-2xyuA:
37.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_A_1N1A1_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
TYR A 701
SER A 763
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.2A)
 0.65A 3sxrA-2xyuA:
32.1		 3sxrA-2xyuA:
37.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3SXR_B_1N1B2_1
(CYTOPLASMIC
TYROSINE-PROTEIN
KINASE BMX)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
SER A 763
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.68A 3sxrB-2xyuA:
31.7		 3sxrB-2xyuA:
37.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_A_DB8A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
ILE A 697
THR A 699
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.39A 3ue4A-2xyuA:
33.3		 3ue4A-2xyuA:
38.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3UE4_B_DB8B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.42A 3ue4B-2xyuA:
27.4		 3ue4B-2xyuA:
38.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3V5W_A_8PRA701_1
(G-PROTEIN COUPLED
RECEPTOR KINASE 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ILE A 627
GLY A 630
GLY A 633
VAL A 635
ALA A 651
LYS A 653
 None
None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
 0.57A 3v5wA-2xyuA:
21.8		 3v5wA-2xyuA:
16.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_2
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 ILE A 673
ILE A 682
ILE A 683
TYR A 701
MET A 702
 None
None
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-4.8A)
None
 0.42A 3zosA-2xyuA:
24.2		 3zosA-2xyuA:
35.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_A_0LIA1000_2
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 9 ILE A 673
MET A 674
ILE A 683
TYR A 701
MET A 702
 None
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-4.8A)
None
 0.77A 3zosA-2xyuA:
24.2		 3zosA-2xyuA:
35.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3ZOS_B_0LIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
ILE A 683
THR A 699
LEU A 737
HIS A 744
LEU A 753
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
None
None
Q9G  A1898 (-4.3A)
None
 0.77A 3zosB-2xyuA:
24.2		 3zosB-2xyuA:
35.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANQ_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 VAL A 635
ALA A 651
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.61A 4anqA-2xyuA:
33.5		 4anqA-2xyuA:
34.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4ANS_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 VAL A 635
ALA A 651
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.58A 4ansA-2xyuA:
27.2		 4ansA-2xyuA:
34.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_A_STIA1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 VAL A 635
ALA A 651
ILE A 673
MET A 674
ILE A 683
THR A 699
TYR A 701
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 0.98A 4bkjA-2xyuA:
27.3		 4bkjA-2xyuA:
35.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4BKJ_B_STIB1000_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
ILE A 673
MET A 674
ILE A 683
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.86A 4bkjB-2xyuA:
27.1		 4bkjB-2xyuA:
35.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
ILE A 697
THR A 699
HIS A 744
LEU A 753
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 (-4.3A)
None
 0.83A 4c8bA-2xyuA:
27.9		 4c8bA-2xyuA:
28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_A_0LIA1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 5 VAL A 635
ILE A 682
TYR A 701
MET A 702
 Q9G  A1898 ( 4.7A)
None
Q9G  A1898 (-4.8A)
None
 0.37A 4c8bA-2xyuA:
27.9		 4c8bA-2xyuA:
28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_1
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
ILE A 682
THR A 699
HIS A 744
LEU A 753
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 (-3.5A)
None
Q9G  A1898 (-4.3A)
None
 0.79A 4c8bB-2xyuA:
27.8		 4c8bB-2xyuA:
28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4C8B_B_0LIB1000_2
(RECEPTOR-INTERACTING
SERINE/THREONINE-PRO
TEIN KINASE 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		3 / 3 TYR A 701
MET A 702
ILE A 682
 Q9G  A1898 (-4.8A)
None
None
 0.58A 4c8bB-2xyuA:
27.8		 4c8bB-2xyuA:
28.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 11 GLY A 628
VAL A 635
ALA A 651
TYR A 701
GLY A 705
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.59A 4ckiA-2xyuA:
27.4		 4ckiA-2xyuA:
34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKI_A_ADNA2022_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 11 GLY A 628
VAL A 635
TYR A 701
GLY A 705
SER A 706
LEU A 753
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 ( 4.5A)
Q9G  A1898 (-4.3A)
 0.81A 4ckiA-2xyuA:
27.4		 4ckiA-2xyuA:
34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CKJ_A_ADNA2014_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE RECEPTOR RET)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 10 GLY A 628
GLY A 630
VAL A 635
ALA A 651
TYR A 701
LEU A 753
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
 0.58A 4ckjA-2xyuA:
28.7		 4ckjA-2xyuA:
34.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4CSV_A_STIA1265_1
(SRC-ABL TYROSINE
KINASE ANCESTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
ILE A 673
MET A 674
THR A 699
TYR A 701
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 0.76A 4csvA-2xyuA:
28.7		 4csvA-2xyuA:
45.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4HJO_A_AQ4A1001_1
(EPIDERMAL GROWTH
FACTOR RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
LYS A 653
THR A 699
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.63A 4hjoA-2xyuA:
30.9		 4hjoA-2xyuA:
35.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
 0.61A 4mxoA-2xyuA:
16.2		 4mxoA-2xyuA:
43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXO_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.44A 4mxoB-2xyuA:
27.9		 4mxoB-2xyuA:
43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.57A 4mxxA-2xyuA:
27.6		 4mxxA-2xyuA:
43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_A_DB8A601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.73A 4mxxA-2xyuA:
27.6		 4mxxA-2xyuA:
43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
LYS A 653
THR A 699
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.56A 4mxxB-2xyuA:
29.6		 4mxxB-2xyuA:
43.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4MXX_B_DB8B601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
THR A 699
TYR A 701
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.36A 4mxxB-2xyuA:
29.6		 4mxxB-2xyuA:
43.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ILE A 627
ALA A 651
LYS A 653
ILE A 697
LEU A 753
ASP A 764
LYS A 713
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-4.3A)
None
None
 1.37A 4qmnA-2xyuA:
19.4		 4qmnA-2xyuA:
27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMN_A_DB8A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ILE A 627
ALA A 651
LYS A 653
ILE A 697
TYR A 701
LEU A 753
LYS A 713
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
None
 1.23A 4qmnA-2xyuA:
19.4		 4qmnA-2xyuA:
27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMS_A_1N1A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 11 ILE A 627
ALA A 651
LYS A 653
ILE A 697
TYR A 701
LEU A 753
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
 0.67A 4qmsA-2xyuA:
19.4		 4qmsA-2xyuA:
27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4QMZ_A_B49A401_1
(SERINE/THREONINE-PRO
TEIN KINASE 24)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ILE A 627
GLY A 628
VAL A 635
ALA A 651
TYR A 701
LEU A 753
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
 0.57A 4qmzA-2xyuA:
19.4		 4qmzA-2xyuA:
27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4R7I_A_STIA1001_1
(MACROPHAGE
COLONY-STIMULATING
FACTOR 1 RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.91A 4r7iA-2xyuA:
27.2		 4r7iA-2xyuA:
30.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4RZ7_A_1E8A901_1
(CGMP-DEPENDENT
PROTEIN KINASE,
PUTATIVE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 10 ILE A 627
ALA A 651
LYS A 653
ILE A 683
THR A 699
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
 0.48A 4rz7A-2xyuA:
7.9		 4rz7A-2xyuA:
15.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RZV_A_032A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
LYS A 653
ILE A 697
THR A 699
SER A 706
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 4.5A)
 0.70A 4rzvA-2xyuA:
7.7		 4rzvA-2xyuA:
31.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4RZV_B_032B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
LYS A 653
THR A 699
SER A 706
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 4.5A)
 0.75A 4rzvB-2xyuA:
26.6		 4rzvB-2xyuA:
31.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U0I_A_0LIA1001_2
(MAST/STEM CELL
GROWTH FACTOR
RECEPTOR
KIT,MAST/STEM CELL
GROWTH FACTOR
RECEPTOR KIT)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ALA A 651
LYS A 653
THR A 699
GLY A 705
HIS A 744
LEU A 753
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
None
Q9G  A1898 (-4.3A)
None
 0.87A 4u0iA-2xyuA:
32.6		 4u0iA-2xyuA:
33.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 9 VAL A 635
ALA A 651
TYR A 701
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.44A 4u5jB-2xyuA:
27.6		 4u5jB-2xyuA:
43.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4UXQ_A_0LIA1752_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 4)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 VAL A 635
LYS A 653
MET A 674
ILE A 683
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
 0.68A 4uxqA-2xyuA:
28.8		 4uxqA-2xyuA:
34.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_A_0LIA1776_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
MET A 674
LEU A 737
HIS A 744
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
None
None
None
 0.78A 4v01A-2xyuA:
27.0		 4v01A-2xyuA:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_B_0LIB1770_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
MET A 674
LEU A 737
HIS A 744
ASP A 764
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
None
None
None
 0.76A 4v01B-2xyuA:
27.1		 4v01B-2xyuA:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V01_B_0LIB1770_2
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 VAL A 635
LYS A 653
ILE A 683
TYR A 701
ARG A 745
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 (-4.3A)
 0.77A 4v01B-2xyuA:
27.1		 4v01B-2xyuA:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4V04_B_0LIB1771_1
(FIBROBLAST GROWTH
FACTOR RECEPTOR 1
(FMS-RELATED
TYROSINE KINASE 2,
PFEIFFER SYNDROME),
ISOFORM CRA_B)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 10 VAL A 635
LYS A 653
MET A 674
ILE A 683
TYR A 701
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.3A)
 0.84A 4v04B-2xyuA:
28.1		 4v04B-2xyuA:
33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_A_AXIA9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 11 ALA A 651
LYS A 653
THR A 699
MET A 702
GLY A 705
ASN A 751
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
None
Q9G  A1898 (-4.3A)
 1.04A 4wa9A-2xyuA:
29.1		 4wa9A-2xyuA:
38.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4WA9_B_AXIB9000_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
THR A 699
MET A 702
GLY A 705
ASN A 751
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
None
Q9G  A1898 (-4.3A)
 0.77A 4wa9B-2xyuA:
32.4		 4wa9B-2xyuA:
38.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XEY_A_1N1A601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.69A 4xeyA-2xyuA:
33.2		 4xeyA-2xyuA:
29.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XEY_B_1N1B601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
MET A 674
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.52A 4xeyB-2xyuA:
32.5		 4xeyB-2xyuA:
29.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_A_1N1A601_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.66A 4xliA-2xyuA:
27.2		 4xliA-2xyuA:
38.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4XLI_B_1N1B600_1
(NON-SPECIFIC
PROTEIN-TYROSINE
KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.53A 4xliB-2xyuA:
29.0		 4xliB-2xyuA:
38.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAA_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 VAL A 635
ALA A 651
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.67A 5aaaA-2xyuA:
26.4		 5aaaA-2xyuA:
34.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5AAC_A_VGHA9000_1
(ALK TYROSINE KINASE
RECEPTOR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 10 VAL A 635
ALA A 651
LYS A 653
MET A 702
GLY A 705
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
None
 0.81A 5aacA-2xyuA:
33.4		 5aacA-2xyuA:
35.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BVW_A_1N1A1009_1
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 683
THR A 699
TYR A 701
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.62A 5bvwA-2xyuA:
27.0		 5bvwA-2xyuA:
35.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_A_1N1A501_1
(PROTEIN-TYROSINE
KINASE 6)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.44A 5h2uA-2xyuA:
26.7		 5h2uA-2xyuA:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_B_1N1B501_1
(PROTEIN-TYROSINE
KINASE 6)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.53A 5h2uB-2xyuA:
26.7		 5h2uB-2xyuA:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_C_1N1C501_1
(PROTEIN-TYROSINE
KINASE 6)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 ALA A 651
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.49A 5h2uC-2xyuA:
26.7		 5h2uC-2xyuA:
38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5H2U_D_1N1D504_1
(PROTEIN-TYROSINE
KINASE 6)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
ILE A 697
THR A 699
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.49A 5h2uD-2xyuA:
26.8		 5h2uD-2xyuA:
38.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_A_032A401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
ILE A 683
ILE A 697
THR A 699
TYR A 701
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
 0.59A 5hesA-2xyuA:
11.2		 5hesA-2xyuA:
29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5HES_B_032B401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE
KINASE KINASE MLT)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
 0.32A 5hesB-2xyuA:
27.3		 5hesB-2xyuA:
29.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_A_P06A801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
 0.56A 5hieA-2xyuA:
26.6		 5hieA-2xyuA:
30.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_B_P06B801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
 0.56A 5hieB-2xyuA:
26.6		 5hieB-2xyuA:
30.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5HIE_D_P06D801_1
(SERINE/THREONINE-PRO
TEIN KINASE B-RAF)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 12 VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
 0.56A 5hieD-2xyuA:
26.6		 5hieD-2xyuA:
30.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9X_A_DB8A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		10 / 12 ILE A 627
ALA A 651
LYS A 653
ILE A 683
ILE A 697
THR A 699
TYR A 701
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.62A 5i9xA-2xyuA:
38.0		 5i9xA-2xyuA:
71.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9Y_A_1N1A1001_1
(EPHRIN TYPE-A
RECEPTOR 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 ILE A 627
ALA A 651
LYS A 653
MET A 674
THR A 699
TYR A 701
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.60A 5i9yA-2xyuA:
32.4		 5i9yA-2xyuA:
71.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5I9Y_A_1N1A1001_2
(EPHRIN TYPE-A
RECEPTOR 2)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		3 / 3 ILE A 683
ILE A 697
MET A 702
 Q9G  A1898 ( 4.9A)
Q9G  A1898 ( 4.6A)
None
 0.35A 5i9yA-2xyuA:
32.4		 5i9yA-2xyuA:
71.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_F_AZ1F2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR-DAR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 GLY A 628
GLY A 630
GLY A 633
VAL A 635
 None
None
None
Q9G  A1898 ( 4.7A)
 0.33A 5izjB-2xyuA:
17.5		 5izjB-2xyuA:
24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5IZJ_G_AZ1G2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAR-DAR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 GLY A 628
GLY A 630
VAL A 635
LYS A 653
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
 0.42A 5izjA-2xyuA:
22.5		 5izjA-2xyuA:
24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5J5X_B_AZ1B2_1
(CAMP-DEPENDENT
PROTEIN KINASE
CATALYTIC SUBUNIT
ALPHA
47P-AZ1-DAL-DAR-DAR-
DAR-DAR)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 GLY A 628
GLY A 630
VAL A 635
LYS A 653
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
 0.33A 5j5xA-2xyuA:
21.8		 5j5xA-2xyuA:
24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LW1_B_ADNB401_1
(MITOGEN-ACTIVATED
PROTEIN KINASE 8)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 9 ILE A 627
GLY A 628
VAL A 635
ALA A 651
ILE A 683
MET A 702
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.9A)
None
 0.86A 5lw1B-2xyuA:
20.2		 5lw1B-2xyuA:
15.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MAF_A_XINA403_1
(MATERNAL EMBRYONIC
LEUCINE ZIPPER
KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ILE A 627
GLY A 628
VAL A 635
ALA A 651
LYS A 653
TYR A 701
GLY A 705
 None
None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
 0.69A 5mafA-2xyuA:
24.3		 5mafA-2xyuA:
13.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5MO4_A_NILA601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		5 / 10 VAL A 635
LYS A 653
ILE A 697
MET A 702
GLY A 705
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
None
Q9G  A1898 ( 3.8A)
 0.52A 5mo4A-2xyuA:
27.9		 5mo4A-2xyuA:
25.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5P9I_A_1E8A701_1
(TYROSINE-PROTEIN
KINASE BTK)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 VAL A 635
ALA A 651
ILE A 697
THR A 699
GLY A 705
LEU A 753
SER A 763
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.61A 5p9iA-2xyuA:
27.8		 5p9iA-2xyuA:
38.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5VC3_A_DB8A601_1
(WEE1-LIKE PROTEIN
KINASE)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 ILE A 627
GLY A 628
ALA A 651
TYR A 701
GLY A 705
ASP A 764
 None
None
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 3.8A)
None
 0.79A 5vc3A-2xyuA:
23.6		 5vc3A-2xyuA:
26.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6BSD_A_1N1A901_0
(EPITHELIAL DISCOIDIN
DOMAIN-CONTAINING
RECEPTOR 1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		10 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 683
THR A 699
TYR A 701
MET A 702
GLY A 705
LEU A 753
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.8A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
 0.62A 6bsdA-2xyuA:
31.5		 6bsdA-2xyuA:
15.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		9 / 12 ILE A 627
VAL A 635
ALA A 651
ILE A 697
THR A 699
MET A 702
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
None
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.59A 6fnmA-2xyuA:
34.3		 6fnmA-2xyuA:
77.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		7 / 12 ILE A 627
VAL A 635
ALA A 651
LYS A 653
ILE A 697
THR A 699
SER A 763
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-3.2A)
 0.81A 6fnmA-2xyuA:
34.3		 6fnmA-2xyuA:
77.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6FNM_A_1N1A1001_1
(-)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 ILE A 627
VAL A 635
ALA A 651
MET A 674
THR A 699
GLY A 705
LEU A 753
SER A 763
 None
Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
Q9G  A1898 ( 3.8A)
Q9G  A1898 (-4.3A)
Q9G  A1898 (-3.2A)
 0.95A 6fnmA-2xyuA:
34.3		 6fnmA-2xyuA:
77.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_A_STIA604_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.77A 6hd4A-2xyuA:
32.4		 6hd4A-2xyuA:
14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD4_B_STIB602_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.78A 6hd4B-2xyuA:
32.1		 6hd4B-2xyuA:
14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_A_STIA603_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		8 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
ILE A 697
THR A 699
LEU A 753
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 ( 4.6A)
Q9G  A1898 (-3.5A)
Q9G  A1898 (-4.3A)
None
 0.73A 6hd6A-2xyuA:
32.3		 6hd6A-2xyuA:
14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_0
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		6 / 12 VAL A 635
ALA A 651
LYS A 653
MET A 674
THR A 699
ASP A 764
 Q9G  A1898 ( 4.7A)
Q9G  A1898 (-3.2A)
Q9G  A1898 (-4.8A)
Q9G  A1898 (-3.9A)
Q9G  A1898 (-3.5A)
None
 0.46A 6hd6B-2xyuA:
32.0		 6hd6B-2xyuA:
14.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
6HD6_B_STIB601_1
(TYROSINE-PROTEIN
KINASE ABL1)		 2xyu EPHRIN TYPE-A
RECEPTOR 4,
(Mus
musculus) 		4 / 7 ILE A 697
MET A 702
GLY A 705
ARG A 745
 Q9G  A1898 ( 4.6A)
None
Q9G  A1898 ( 3.8A)
None
 0.90A 6hd6B-2xyuA:
32.0		 6hd6B-2xyuA:
14.79